Importantly, we define PTEN as a direct target of miR-494 in CLL and DLBCL cells by two independent approaches: (i) miR-494 modulation both by an inhibitor and a mimic, and (ii) a luciferase reporter assay, consistent with independent investigations showing PTEN as a direct target in various cancers, including hepatocellular carcinoma [42], colorectal cancer [45], and non-small cell lung cancer [46]. This evidence concerns the gene PTEN and B-cell chronic lymphocytic leukemia.